Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Cancer Prevention Vaccine (Nous-209) for People with Lynch Syndrome
Glossary on
off
Printer Friendly Page Cancer Prevention Vaccine (Nous-209) for People with Lynch Syndrome

Cancer Prevention Vaccine (Nous-209) for People with Lynch Syndrome

Clinicaltrials.gov identifier:
NCT05078866


Prevention study for people with Lynch syndrome


Cancer Prevention Vaccine (Nous-209) for People with Lynch Syndrome

About the Study

This study is no longer enrolling people. 

 

This study is testing a vaccine, known as the Nous-209 vaccine, which is intended to decrease the chances that people with will develop that can turn into cancer.

People with who enroll in the study will participate for one year. It evaluates the safety and effectiveness of the Nous-209 vaccine in people affected with .

 

 

This Study is Open To:

This study is no longer enrolling people. 

This Study is Not Open To:

This study is no longer enrolling people.